Albert Labs International (XCNQ:ABRT) EBIT : C$0.61 Mil (TTM As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Albert Labs International EBIT?

Albert Labs International's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2023 was C$-0.02 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was C$0.61 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Albert Labs International's annualized ROC % for the quarter that ended in Sep. 2023 was -37.16%. Albert Labs International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -122.52%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Albert Labs International's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 40.72%.

Albert Labs International EBIT Historical Data

The historical data trend for Albert Labs International's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albert Labs International EBIT Chart

Albert Labs International Annual Data

Trend

Dec21

Dec22

EBIT

-1.88

-4.14

Albert Labs International Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBIT	Get a 7-Day Free Trial					-0.54	1.17	-0.39	-0.16	-0.02

Competitive Comparison of Albert Labs International's EBIT

For the Biotechnology subindustry, Albert Labs International's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Albert Labs International's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Albert Labs International's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Albert Labs International's EV-to-EBIT falls into.

Albert Labs International EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.61 Mil.

Albert Labs International (XCNQ:ABRT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Albert Labs International's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

	ROC % (Q: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Sep. 2023 ))	/ count )
=	-0.068 * ( 1 - 0% )	/	( (0.186	+	0.18)	/ 2 )
=	-0.068	/	0.183
=	-37.16 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.071	-	0.37	-	( 0	-	max(0, 0.498	-	0.013	+	0	))
=	0.186

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.065	-	0.37	-	( 0	-	max(0, 0.498	-	0.013	+	0	))
=	0.18

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Albert Labs International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Sep. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-0.068	/	( ( (0.059 + max(-0.485, 0))	+	(0.052 + max(-0.485, 0)) )	/	2 )
=	-0.068	/	( ( 0.059	+	0.052 )	/	2 )
=	-0.068	/	0.0555
=	-122.52 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.013)	-	(0.37	+	0	+	0.128)
=	-0.485

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.013)	-	(0.37	+	0	+	0.128)
=	-0.485

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Albert Labs International's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2023 )
	=	0.61	/	1.498
	=	40.72 %

Albert Labs International EBIT Related Terms

Thank you for viewing the detailed overview of Albert Labs International's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Albert Labs International (XCNQ:ABRT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albert Labs International Corp (XCNQ:ABRT) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

6996, Merritt Avenue, Burnaby, BC, CAN, V5J 4R6

Website

https://www.albertlabs.com

Albert Labs International Corp is a laboratory-based, clinical research and drug development enterprise addressing mental health care needs. The company is focusing on Real World Evidence (RWE) the company will initially look to commercialize its mycelium-based KRN-101 medicine and treatment with the help of clinical pathway.

Albert Labs International (XCNQ:ABRT) Headlines

No Headlines